They completed the study..
Aethlon Medical Inc. has added a news release to its Investor Relations website.
Title: Aethlon Medical Completes First Medical Device Study to Treat HIV/AIDS
Date: 1/26/2009 9:19:00 AM
For a complete listing of our news releases, please click here
SAN DIEGO--(BUSINESS WIRE)--Jan. 26, 2009--Aethlon Medical, Inc. (OTCBB:AEMD) announced today that it has completed
the "first-in-man" study of a medical device to treat Human
Immunodeficiency Virus (HIV), the disease that causes Acquired Immune
Deficiency Syndrome (AIDS). In the study, an HIV-infected individual
completed a twelve treatment study of the Aethlon Hemopurifier(R)
administered thrice weekly over the course of 30-days. The Hemopurifier(R)
is a therapeutic filtration device that serves as an artificial adjunct
to the immune system. In HIV care the Hemopurifier(R) targets the
clearance of all circulating strains of infectious HIV, including those
varieties that cause patients to fail antiviral drug regimens.
Additionally, the device assists to preserve immune response through the
removal of gp120 and other toxic proteins shed by HIV to kill-off immune
cells, the hallmark of AIDS. The study was conducted at the Sigma New
Life Hospital in Punjab, India. Initial viral load and immune cell data
resulting from the study are expected to be available for disclosure in
mid-February.
"Based on previous treatment outcomes in Hepatitis-C patients, we are
cautiously optimistic that the data resulting from our first HIV study
will also prove to be positive," stated Jim Joyce, Chairman and CEO of
Aethlon Medical. "The principal investigator of our study has reported
all twelve Hemopurifier(R) treatments were completed without any observed
adverse events, and that the patient feels an improved sense of well
being, including increased energy and appetite," concluded Joyce.
In a previous infectious disease study, treatment with the Hemopurifier(R)
resulted in robust viral load reductions in Hepatitis-C (HCV) infected
patients who completed a treatment protocol of three, 4-hour
Hemopurifier(R) treatments every other day during the course of one week.
The Study was conducted at the Fortis Hospital in Delhi, India.
Patient #1 had a 95% reduction three days post treatment and 89%
reduction seven days post treatment. The initial viral load for patient
1 was 5.3 x 10(5) viral units per ml of blood (IU/ml). Patient 1's viral
load seven days post treatment was 5.7 x 10(4) IU/ml.
Patient #2 had a 85% reduction three days post treatment and 50%
reduction seven days post treatment. The initial viral load for patient
2 was 9.2 x 10(6) IU/ml. Patient 2's viral load seven days post
treatment was 4.6 x 10(6) IU/ml.
Patient #3 had a 60% reduction three days post treatment and 83%
reduction seven days post treatment. The initial viral load for patient
3 was 3.0 x 10(8) IU/ml. Patient 3's viral load seven days post
treatment was 5.1 x 10(7) IU/ml. All viral load measurements were
performed with real-time quantitative polymerase chain reaction
(RT-PCR). Control samples were measured in duplicate while treatment
samples were generally measured in triplicate.
